独家-艾伯维接近以约 80 亿美元收购药物开发商 Cerevel--消息人士_老虎社区_美港股上老虎

独家-艾伯维接近以约 80 亿美元收购药物开发商 Cerevel--消息人士

Reuters2023-12-07

(添加背景信息，分享反应) David Carnevali

路透纽约12月6日 - 熟悉内情的人士周三表示，艾伯维公司即将以约80亿美元的价格收购Cerevel Therapeutics Holdings Inc ，后者是帕金森等神经系统疾病的药物开发商。

就在艾伯维同意以101亿美元现金收购癌症药物开发商ImmunoGen Inc 之后几天， (link) ，这凸显了艾伯维在有前景的新药上下大赌注的胃口。

消息人士称，艾伯维正在谈判以每股约45美元的价格收购Cerevel公司，该公司得到了私募股权公司贝恩资本的支持。

消息人士补充说，如果谈判顺利结束，交易最早可能在本周宣布，但他们要求匿名，因为此事属于机密。

艾伯维和 Cerevel 没有立即回应置评请求。

在周三的纽约盘后交易中，Cerevel股价大涨14%至42.20美元。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2389069686?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-12-07 05:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2389069686","market":"us","top_or_hot":-1,"title":"独家-艾伯维接近以约 80 亿美元收购药物开发商 Cerevel--消息人士","media":"Reuters","content":"<html><body><p>(添加背景信息，分享反应) David  Carnevali</p><p>    路透纽约12月6日 - 熟悉内情的人士周三表示，<a href=\"https://laohu8.com/S/ABBV\">艾伯维公司</a>  即将以约80亿美元的价格收购Cerevel Therapeutics Holdings Inc  ，后者是帕金森等神经系统疾病的药物开发商。</p><p>就 在艾伯维同意以101亿美元现金收购癌症药物开发商<a href=\"https://laohu8.com/S/IMGN\">ImmunoGen</a> Inc   之后 几天， (link)  ，这  凸显了艾伯维在有前景的新药上下大赌注的胃口 。 </p><p>消息人士称，艾伯维正在谈判以每股约45美元的价格收购Cerevel公司，该公司得到了私募股权公司贝恩资本的支持。</p><p>消息人士补充说，如果谈判顺利结束，交易最早可能在本周宣布，但他们要求匿名，因为此事属于机密。</p><p>艾伯维和 Cerevel 没有立即回应置评请求。</p><p>在周三的纽约盘后交易中，Cerevel股价大涨14%至42.20美元。 </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>独家-艾伯维接近以约 80 亿美元收购药物开发商 Cerevel--消息人士</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n独家-艾伯维接近以约 80 亿美元收购药物开发商 Cerevel--消息人士\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-12-07 05:11 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(添加背景信息，分享反应) David  Carnevali    路透纽约12月6日 - 熟悉内情的人士周三表示，艾伯维公司  即将以约80亿美元的价格收购Cerevel Therapeutics Holdings Inc  ，后者是帕金森等神经系统疾病的药物开发商。就 在艾伯维同意以101亿美元现金收购癌症药物开发商ImmunoGen Inc   之后 几天， (link)  ，这  凸显了...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2389069686","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2389069686","pubTimestamp":1701897077,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":" David  Carnevali    路透纽约12月6日 - 熟悉内情的人士周三表示，艾伯维公司  即将以约80亿美元的价格收购Cerevel Therapeutics Holdings Inc  ，后者是帕金森等神经系统疾病的药物开发商。消息人士称，艾伯维正在谈判以每股约45美元的价格收购Cerevel公司，该公司得到了私募股权公司贝恩资本的支持。艾伯维和 Cerevel 没有立即回应置评请求。在周三的纽约盘后交易中，Cerevel股价大涨14%至42.20美元。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4581":"高盛持仓","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","CERE":"Cerevel Therapeutics Holdings, Inc.","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","BK4139":"生物科技","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0882574055.USD":"富达全球健康医疗A ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","ABBV":"艾伯维公司","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","BK4588":"碎股","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","IMGN":"ImmunoGen"},"translate_title":"EXCLUSIVE-Albertville is close to acquiring drug developer Cerevel for about $8 billion-source","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":0.9,"CERE":0.9,"IMGN":0.9},"content_text":"(添加背景信息，分享反应) David  Carnevali    路透纽约12月6日 - 熟悉内情的人士周三表示，艾伯维公司  即将以约80亿美元的价格收购Cerevel Therapeutics Holdings Inc  ，后者是帕金森等神经系统疾病的药物开发商。就 在艾伯维同意以101亿美元现金收购癌症药物开发商ImmunoGen Inc   之后 几天， (link)  ，这  凸显了艾伯维在有前景的新药上下大赌注的胃口 。 消息人士称，艾伯维正在谈判以每股约45美元的价格收购Cerevel公司，该公司得到了私募股权公司贝恩资本的支持。消息人士补充说，如果谈判顺利结束，交易最早可能在本周宣布，但他们要求匿名，因为此事属于机密。艾伯维和 Cerevel 没有立即回应置评请求。在周三的纽约盘后交易中，Cerevel股价大涨14%至42.20美元。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}